GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Return-on-Tangible-Equity

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Return-on-Tangible-Equity : 7.88% (As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. GlaxoSmithKline Consumer Nigeria's annualized net income for the quarter that ended in Jun. 2023 was ₦738 Mil. GlaxoSmithKline Consumer Nigeria's average shareholder tangible equity for the quarter that ended in Jun. 2023 was ₦9,373 Mil. Therefore, GlaxoSmithKline Consumer Nigeria's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was 7.88%.

The historical rank and industry rank for GlaxoSmithKline Consumer Nigeria's Return-on-Tangible-Equity or its related term are showing as below:

NSA:GLAXOSMITH' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.84   Med: 7.79   Max: 27.79
Current: 6.54

During the past 13 years, GlaxoSmithKline Consumer Nigeria's highest Return-on-Tangible-Equity was 27.79%. The lowest was 2.84%. And the median was 7.79%.

NSA:GLAXOSMITH's Return-on-Tangible-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.31 vs NSA:GLAXOSMITH: 6.54

GlaxoSmithKline Consumer Nigeria Return-on-Tangible-Equity Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Return-on-Tangible-Equity Chart

GlaxoSmithKline Consumer Nigeria Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.75 10.20 6.81 7.15 8.19

GlaxoSmithKline Consumer Nigeria Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.27 6.66 5.85 12.25 7.88

Competitive Comparison of GlaxoSmithKline Consumer Nigeria's Return-on-Tangible-Equity

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Consumer Nigeria's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's Return-on-Tangible-Equity falls into.



GlaxoSmithKline Consumer Nigeria Return-on-Tangible-Equity Calculation

GlaxoSmithKline Consumer Nigeria's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=771.146/( (9299.45+9532.452 )/ 2 )
=771.146/9415.951
=8.19 %

GlaxoSmithKline Consumer Nigeria's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=738.204/( (9532.452+9214.442)/ 2 )
=738.204/9373.447
=7.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


GlaxoSmithKline Consumer Nigeria  (NSA:GLAXOSMITH) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


GlaxoSmithKline Consumer Nigeria Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines